Chipkin Named Founding Editor-in-Chief of ‘American Journal of Medicine Open’

Image

Research publishing giant Elsevier has announced a new open access companion to the “American Journal of Medicine,” with research professor of kinesiology Dr. Stuart Chipkin, serving as its founding editor-in-chief.

In its press release, Elsevier notes that the “American Journal of Medicine Open” (“AJM Open”) is “dedicated to publishing original clinical research in internal medicine, relevant to academia and community-based practice. All articles will be subject to rigorous peer review. It is a companion journal to “The American Journal of Medicine” (“The Green Journal”) and is similar in scope, publishing original research and reviews in the specialties comprising internal medicine, with an emphasis on papers with immediate clinical interest.”

“AJM Open” has issued a worldwide call for submissions in anticipation of a launch later in 2021. As an open access journal, its articles will be immediately and permanently free for everyone to read, download, copy and distribute.

"My goal is for ‘AJM Open’ to be an innovative forum for practitioners of internal medicine and its specialties by building bridges within health care and extending bridges to new and emerging disciplines,” says Chipkin, a practicing endocrinologist. “We are particularly interested in interdisciplinary research, population management and integration of technology into clinical care. Beyond our publications, we will use social media and related platforms to inform providers of innovations in internal medicine and its specialties.”

After earning his B.S. from Emory University and M.D. from SUNY Downstate, Chipkin trained in Internal Medicine and completed a fellowship in endocrinology at the University of Massachusetts Medical School. He joined the faculty of Boston University School of Medicine and developed programs in diabetes care for minority populations. His research efforts transitioned from cellular glucose transport to clinical studies related to lowering cardiovascular risk in insulin resistant states. He also initiated standardized clinical approaches for the care of transgendered people at Boston University and became a recognized clinical expert in the field.

Chipkin subsequently joined a major affiliate of Tufts University where he became chief of endocrinology, diabetes and metabolism. There, he developed collaborations with faculty at UMass Amherst and ultimately joined the faculty at UMass Amherst in 2004. He also became co-PI for a Public Health Training Center emphasizing the roles of front-line health care workers in communities of color. His efforts have continued to emphasize the role of lifestyle changes on insulin resistant states including interactions with medications, exercise timing, nutrient composition and aging. His work has been funded by the National Institutes of Health, the Health Resources & Services Administration, the American Diabetes Association, the American Heart Association and the JDRF.

Chipkin served on the Grant Review Panel and Scientific Sessions Committee for the American Diabetes Association and was the principal medical consultant to initial guidelines for diabetes care in Massachusetts. He has been recognized by several organizations for his work in nutrition and public health. He has also maintained a strong clinical interest in areas related to diabetes, lipids, metabolic syndrome and the care of transgendered people.